The anticancer effects of HDAC inhibitors require the immune system

West, Alison C., Smyth, Mark J. and Johnstone, Ricky W. (2014) The anticancer effects of HDAC inhibitors require the immune system. OncoImmunology, 3 1: 1-3. doi:10.4161/onci.27414

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author West, Alison C.
Smyth, Mark J.
Johnstone, Ricky W.
Title The anticancer effects of HDAC inhibitors require the immune system
Journal name OncoImmunology   Check publisher's open access policy
ISSN 2162-402X
Publication date 2014-01-01
Year available 2014
Sub-type Article (original research)
DOI 10.4161/onci.27414
Open Access Status Not Open Access
Volume 3
Issue 1
Start page 1
End page 3
Total pages 3
Place of publication Philadelphia, PA, United States
Publisher Taylor & Francis
Language eng
Abstract Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFNγ). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic.
Keyword Anticancer immunity
Anticancer therapy
Epigenetic regulatory agent
Immunogenic cell death
Q-Index Code CX
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article number e27414

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
Official Audit
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 27 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 27 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 20 May 2014, 11:56:41 EST by System User on behalf of Medicine - Royal Brisbane and Women's Hospital